Parkinson’s

Cell and gene therapies
#AskBio #Gene therapy #Neurodegenerative disorders #Parkinson's #Phase II trial

Gene therapy for Parkinson’s disease progresses to Phase II

A new Phase II trial, REGENERATE-PD, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of moderate-stage Parkinson’s disease. The trial will include an estimated 87 subjects with study sites located in the US, UK and… Read More

#News

Neuroscience Parkinson's disease
#Bayer #Biogen #BlueRock Therapeutics #Cell therapy #Ionis Pharmaceuticals #Mission Therapeutics #Neuroscience #Parkinson's #Small molecul #Stem cells #Vaxxinity #Vesper Bio

Exploring new frontiers in Parkinson’s Disease   

With debilitating symptoms including tremor, slow movement, rigidness and pain, Parkinson’s disease remains one of the most feared neurodegenerative conditions. DDW's Megan Thomas reports on the latest clinical progress as pharma and biotech search for new therapies for this currently incurable condition.  Parkinson’s is the most common movement disorder, affecting around… Read More

#Exclusive Content #Trends & Analysis

Neurons in a brain with Alzheimer's disease
#Alchemab Therapeutics #Funding #Neuroscience #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

Novel antibody with potential in Parkinson’s disease  

Alchemab Therapeutics has been awarded a grant of $595,000 by The Michael J Fox Foundation for Parkinson’s Research (MJFF) to support its Parkinson’s disease (PD) programme.  The grant will fund research performed at Alchemab following its identification of antibodies that target prostaglandin biology in PD, a potentially unique… Read More

#News

Dementia
#CNS #IRLAB Therapeutics #Neurodegenerative disorders #Parkinson's #Phase I trial

Drug candidate for apathy enters Phase I trials

Swedish company IRLAB Therapeutics has initiated a Phase I study of IRL757, its drug candidate for apathy – a condition associated with Parkinson’s disease and other CNS diseases. IRL757 has shown positive effects in several preclinical models of cognitive function, including improved motivation. This… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Clinical trial #Clinical trials #Cystic fibrosis #Parkinson's #TB

New DDW Highlights podcast: 22 April 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The headline news this week all concerns clinical trials for new drugs that could… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Clinical trial #Clinical trials #Cystic fibrosis #Parkinson's #TB

This week in drug discovery (15-19 April) 

News round-up for 15-19 April by DDW Digital Content Editor Diana Spencer. The headline news this week all concerns clinical trials for new drugs that could have a significant impact on future patient treatment, including trials testing therapeutics for ALS, cystic fibrosis, gonorrhoea, TB and Parkinson’s. Read More

#News

Parkinson's disease
#AskBio #Cell and gene therapy #Gene therapy #Neurodegenerative disorders #Parkinson's #Phase II trial

Gene therapy proved to be safe in patients with Parkinson’s disease

Askbio’s AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the treatment of Parkinson’s disease, was well tolerated with no serious adverse events in a Phase Ib clinical trial. The data were presented at the American Academy of Neurology 2024 Annual Meeting in Denver, Colorado,… Read More

#News #Trending News

#Alzheimer's #Amyotrophic lateral sclerosis (ALS) #Autism #Neurodegenerative disorders #Neuroscience #Parkinson's

New DDW Highlights podcast: 18 March 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon,… Read More

#News

#Alzheimer's #Amyotrophic lateral sclerosis (ALS) #Autism #Neurodegenerative disorders #Neuroscience #Parkinson's

This week in drug discovery (11-15 March) 

News round-up for 11-15 March by DDW Digital Content Editor Diana Spencer. Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon, Portugal, there have been a number of key announcements regarding investigational therapies for neurological disorders, particularly Alzheimer’s disease and Parkinson’s disease. Read More

#News

#Financing #Mission Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's

£25.2 million raised to progress Parkinson’s treatment

Mission Therapeutics has raised £25.2 ($32.1) million to accelerate development of its lead drug candidates in the area of mitophagy, MTX325 and MTX652, through clinical trials. The financing was jointly led by existing investors Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group, and Rosetta Capital. MTX325… Read More

#Business & Investment #News

#Amplify Therapeutics #BioInnovation Institute #Funding #Fuse Vectors #Metsystem #Parkinson's

Three companies join the BioInnovation Institute programme  

BioInnovation Institute (BII), life science incubator, has announced the addition of six companies who will receive additional financial support through its Venture House programme, created to further support former Venture Lab companies through their next phase of growth. Three of these are key to the advancement of gene therapies,… Read More

#News

#Biologics / Biotechnology #Cell therapy #CNS #Financing #Kenai Therapeutics #Neurology #Parkinson's

$82m investment in cell therapies for neurological diseases

Biotechnology company Kenai Therapeutics has raised $82 million in a Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group. Kenai Therapeutics previously raised seed funding under the name Ryne Bio. “We are grateful for the support of a syndicate of leading life science investors… Read More

#Business & Investment #News

Neuroscience Parkinson's disease
#Clinical trials #Gain Therapeutics #Neuroscience #Parkinson's

Restored motor function in mouse models of Parkinson’s disease  

Gain Therapeutics has announced preclinical data demonstrating that its clinical-stage GCase regulator GT-02287 provided neuroprotection and restored motor function in Parkinson’s disease models following delayed administration.   The data were accepted as a late-breaker abstract and was presented at the 20th Annual WORLDSymposium.  “We… Read More

#News

Parkinson's disease
#Charity #Funding #IRLAB Therapeutics #Parkinson's #The Michael J Fox Foundation

Parkinson’s charity awards $2m to support apathy treatment

Swedish company IRLAB Therapeutics has been awarded funding of over $2 million from The Michael J Fox Foundation for Parkinson’s Research (MJFF). The grant will be used to conduct a Phase I clinical study of IRL757, a drug candidate in development as a novel treatment of… Read More

#News

#Alzheimer's #Cancer research #Cell therapy #CRISPR #Drug discovery #Parkinson's #Plant-based #Stem cells

New DDW Highlights podcast: 4 December 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The key drug discovery news this week focuses on experimental approaches to… Read More

#News

#Alzheimer's #Cancer research #Cell therapy #CRISPR #Drug discovery #Parkinson's #Plant-based #Stem cells

This week in drug discovery (27 Nov – 1 Dec) 

News round-up for 27 November – 1 December by DDW Digital Content Editor Diana Spencer. The key drug discovery news this week focuses on experimental approaches to the treatment of some of the most challenging diseases, including a mathematical model that can simulate Alzheimer’s progression and… Read More

#News